Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 14/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30389317 | 0.83 | MAP3K5 (0.47) | MAP3K5ESR2NR1H2MAPT | |
| SCHEMBL25314447 | 0.83 | MAP3K5 (0.47) | MAP3K5ESR2NR1H2MAPT | |
| SCHEMBL30389781 | 0.83 | MAP3K5 (0.44) | MAP3K5MAPK8 | |
| SCHEMBL24127437 | 0.83 | MAP3K5 (0.44) | MAP3K5MAPK8 | |
| SCHEMBL30595971 | 0.83 | MAP3K5 (0.40) | MAP3K5 | |
| SCHEMBL24127327 | 0.83 | MAP3K5 (0.40) | MAP3K5 | |
| SCHEMBL30596010 | 0.81 | MAP3K5 (0.47) | MAP3K5MAPTMAPK8 | |
| SCHEMBL24127376 | 0.81 | MAP3K5 (0.47) | MAP3K5MAPK8 | |
| SCHEMBL24127440 | 0.81 | MAP3K5 (0.47) | MAP3K5MAPTMAPK8 | |
| SCHEMBL30133720 | 0.81 | MAP3K5 (0.47) | MAP3K5MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552811-B2 | Immunosuppressant, and preparation method therefor and use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2026-02-17 | — | — | US | disclosed |
| CN-115605475-B | Immunosuppressant, preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2025-03-25 | — | — | CN | disclosed |
| US-20230234970-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234970-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| EP-4174066-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-05-03 | — | — | EP | disclosed |
| EP-4174066-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-05-03 | — | — | EP | disclosed |
| CN-115605475-A | Immunosuppressant, preparation method and application thereof | 上海和誉生物医药科技有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| WO-2021254005-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2021-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552811-B2 | Immunosuppressant, and preparation method therefor and use thereof | CD274, PDCD1, PDCD1LG2 | MAP3K5 1802/4885ESR2 3640/4885NR1H2 197/4885 |
| US-20230234970-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CD274, PDCD1, PDCD1LG2 | MAP3K5 341/4885ESR2 4315/4885NR1H2 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.